logo
Share SHARE
FONT-SIZE Plus   Neg

Pitney Bowes Names Marc Lautenbach President, CEO - Quick Facts

Pitney Bowes Inc. (PBI) announced its Board has appointed Marc Lautenbach as President and Chief Executive Officer, effective immediately. Lautenbach succeeds Murray Martin, who is retiring as Chairman, President and Chief Executive Officer and has resigned from board. Martin will continue to work with Lautenbach on an effective transition.

The company also reiterated the guidance it provided on November 1, 2012, and anticipates 2012 guidance for: revenue, excluding the impacts of currency, to remain in a range of flat to a decline of 4 percent when compared to 2011;
adjusted earnings per share from continuing operations to be in the range of $1.95 to $2.15; and GAAP earnings per share from continuing operations to be in the range of $1.78 to $2.08.

Lautenbach has also been appointed to the company's Board, effective immediately. Lautenbach joins the company from IBM. Most recently, Lautenbach served as Managing Partner of IBM North America Global Business Services. Lautenbach has served in various senior management positions of increasing responsibility, including General Manager, IBM North America; General Manager, IBM Global Small and Medium Business; and Vice President, IBM Asia-Pacific Small and Medium Business.

The Pitney Bowes Board also announced Michael Roth, currently Lead Independent Director, has been appointed Non-Executive Chairman of the Board, effective immediately.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
RELATED NEWS
Trade PBI now with 
Follow RTT